Alluvi, known as BI 4744, presents a promising development in obesity therapy. This dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates remarkable efficacy in https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/